Fertility warning
This medicine may affect fertility.
Leaflet AXITINIB STADA 5mg film-coated tablets
- Product code:
- W69502005
- Quantity:
- 56
- Indicated for:
- renal cell carcinoma
- Route of administration:
- oral
- Substance:
- axitinib (tyrosine kinase inhibitor)
- ATC
- L01EK01 — Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
Precautions:
Cytotoxic / special handling
Handle with special care.
Contraception required
Effective contraception is required during treatment.
Contraindicated during breastfeeding
Do not use this medicine while breastfeeding.
Contraindicated during pregnancy
Do not use this medicine during pregnancy.
Avoid grapefruit
Avoid grapefruit and grapefruit juice.
Hepatotoxicity
This medicine may affect the liver.
Major drug interactions
This medicine may have important interactions with other medicines.
Myelosuppression / agranulocytosis
This medicine may lower blood cell counts.
Additional monitoring
This medicine is subject to additional monitoring.
Requires periodic laboratory tests
Periodic laboratory tests may be required during treatment.
Severe skin reactions
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Cardiac risk / QT prolongation / arrhythmias
This medicine may increase the risk of heart rhythm disturbances.
Axitinib is a selective tyrosine kinase inhibitor used in the treatment of advanced renal cell carcinoma. It works by blocking vascular endothelial growth factor receptors (VEGFR), reducing angiogenesis and inhibiting tumor growth.
Axitinib is administered orally, usually twice daily, with the dose adjustable based on patient tolerability and response. It is indicated for patients with advanced renal cell carcinoma who have progressed after prior treatments such as sunitinib or cytokines.
Common side effects include hypertension, diarrhea, fatigue, nausea, and loss of appetite. In rare cases, severe adverse reactions such as thromboembolic events, hemorrhages, or gastrointestinal perforations may occur. Regular monitoring of blood pressure and other clinical parameters is essential during treatment.
Axitinib represents an effective therapeutic option for patients with advanced renal cell carcinoma, contributing to prolonged survival and disease control.
Axitinib is administered orally, usually twice daily, with the dose adjustable based on patient tolerability and response. It is indicated for patients with advanced renal cell carcinoma who have progressed after prior treatments such as sunitinib or cytokines.
Common side effects include hypertension, diarrhea, fatigue, nausea, and loss of appetite. In rare cases, severe adverse reactions such as thromboembolic events, hemorrhages, or gastrointestinal perforations may occur. Regular monitoring of blood pressure and other clinical parameters is essential during treatment.
Axitinib represents an effective therapeutic option for patients with advanced renal cell carcinoma, contributing to prolonged survival and disease control.
General data about AXITINIB STADA 5mg
- Substance:
- axitinib
- Date of latest medicines list:
- 01-06-2026
- Product code:
- W69502005
- Concentration:
- 5mg
- Pharmaceutical form:
- film-coated tablets
- Quantity:
- 56
- Product type:
- Generic medicine
- Price:
- 6280.28 RON
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Concentrations available for axitinib
- 1mg
- 3mg
- 5mg